Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old
reduced child mortality. The World Health Organization (WHO) released conditional guidelines
for this intervention, which include targeting azithromycin distributions to children 1-11
months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate
large-scale implementation of azithromycin to children aged 1-11 months old in the context of
a programmatic setting while monitoring mortality and resistance antimicrobial resistance.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bill and Melinda Gates Foundation Ministry of Health, Niger